Ajanta Pharma Limited — Board Meeting, 28-07-2025: Outcome of Board Meeting

Ajanta Pharma's Q1 FY26 consolidated results show a strong operational quarter. Revenue climbed 14% to Rs 1,303 Cr. Profit after tax (PAT) rose 4% to Rs 255 Cr, but excluding a Rs 25 Cr forex loss, PAT growth was a solid 12%. US Generics business surged 36%, and India's branded generics delivered 16% growth, outperforming the broader market. These segments were key growth drivers, offsetting an 8% decline in Africa institution sales.

#AjantaPharma #Q1FY26 #Pharma